logo dha

DHA

10/03/2025
08:00
Horário oficial: Brasília

10/03/2025
Cardiologia
Português
logo dha

Seguindo

Sobre este conteúdo

Mini Review
Special issue: Renal denervation: Evidence and challenges in clinical practice.
Published: 11 April 2024
Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?)

Keisuke Okamura,
Hideaki Shimada,
Keisuke Imazato,
Hideto Sako,
Akihiro Udo,
Kenichiro Taniguchi,
Shogo Morisaki,
Ichiro Imamura,
Hidenori Urata,
Hisatomi Arima &
Shin-ichiro Miura
Hypertension Research volume 47, pages2652–2658 (2024)Cite this article

 

 

Abstract

The US Food and Drug Administration has approved renal denervation (RDN) as a new treatment option for hypertension (HT) because it not only has antihypertensive effects but also improves the quality of blood pressure (BP) reduction. RDN is expected to be increasingly used in clinical practice in the future. This review summarizes the impact of RDN on quality of life (QOL). Although the treatment of HT aims to improve life prognosis, the use of antihypertensive agents can impair QOL because of adverse effects and lifestyle changes associated with long-term medication use. Consequently, poor adherence to antihypertensive agents is a common problem and may be the most important issue affecting patient QOL. In RDN trials in patients taking antihypertensive agents, approximately 40% of patients had poor adherence to the drugs. Poor adherence is often the cause of resistant hypertension. Therefore, RDN should be well suited to treating HT and improving QOL. Studies have shown that approximately 30% of HT patients prefer RDN to drug treatment. Patients who prefer RDN are typically male and younger and have high BP, poor adherence, and a history of adverse effects of antihypertensive agents. We hope that RDN will improve not only life prognosis but also QOL in HT patients because of its benefits for adherence. Furthermore, we expect that in the future, RDN will be used in other sympathetic nervous system-related diseases, such as heart failure, atrial fibrillation, and sleep apnea syndrome.

 

Mini Review
Special issue: Renal denervation: Evidence and challenges in clinical practice.
Published: 11 April 2024
Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?)

Keisuke Okamura,
Hideaki Shimada,
Keisuke Imazato,
Hideto Sako,
Akihiro Udo,
Kenichiro Taniguchi,
Shogo Morisaki,
Ichiro Imamura,
Hidenori Urata,
Hisatomi Arima &
Shin-ichiro Miura
Hypertension Research volume 47, pages2652–2658 (2024)Cite this article

 

 

Abstract

The US Food and Drug Administration has approved renal denervation (RDN) as a new treatment option for hypertension (HT) because it not only has antihypertensive effects but also improves the quality of blood pressure (BP) reduction. RDN is expected to be increasingly used in clinical practice in the future. This review summarizes the impact of RDN on quality of life (QOL). Although the treatment of HT aims to improve life prognosis, the use of antihypertensive agents can impair QOL because of adverse effects and lifestyle changes associated with long-term medication use. Consequently, poor adherence to antihypertensive agents is a common problem and may be the most important issue affecting patient QOL. In RDN trials in patients taking antihypertensive agents, approximately 40% of patients had poor adherence to the drugs. Poor adherence is often the cause of resistant hypertension. Therefore, RDN should be well suited to treating HT and improving QOL. Studies have shown that approximately 30% of HT patients prefer RDN to drug treatment. Patients who prefer RDN are typically male and younger and have high BP, poor adherence, and a history of adverse effects of antihypertensive agents. We hope that RDN will improve not only life prognosis but also QOL in HT patients because of its benefits for adherence. Furthermore, we expect that in the future, RDN will be used in other sympathetic nervous system-related diseases, such as heart failure, atrial fibrillation, and sleep apnea syndrome.

 

Comentários

Deixe um comentário

17 Aulas
8 Horas

SBC

16 Aulas
15 Horas

Comentários

Deixe um comentário

Thumb (5)
41:57

DIC

Corte
19/02/2024
[Sbc Pr] Reabilitação Cardíaca Pós-Hospitalar - 26/08/21
Íntegra
26/08/2021
Screenshot_2
17:12
Corte
16/03/2023
Slide - 11º Palestra
39:15

DHA

Íntegra
24/04/2021
Sbc Pr
01:18:00
Íntegra
13/03/2024
[Derc] Corte - Insuficiência Cardíaca: Caso Clínico - 05/07/2021
09:08
Corte
05/07/2021
Thumb_Podcast - Dic

DIC

Podcast
13/06/2022
Thumbnail Webinar - Socerj
Íntegra
12/06/2023
Screenshot_2
41:38
Corte
15/01/2024
Thumb-Podcast-Carotida-Online
16:04
13/02/2025
[Sbc Ba] Corte - Ultrassom Pulmonar E Eco Point Of Care - 25/09/2020
22:38
Corte
25/09/2020
Socerj-Corte-Tatiana
10:47
Corte
10/04/2023
[Socerj] Arritmia Na Pandemia
Íntegra
03/08/2020
Thumb Podcast Sbc Mt
Podcast
19/05/2022
Screenshot_5
12:43
Corte
20/05/2023
Carrinho de compras